Working together to maximise success
We are building a pipeline of next generation ADCs to impact the treatment of cancer and are happy to discuss licensing of our ADCs during preclinical and clinical stages with interested parties.
We have novel ADC assets for collaboration and out-license for use in Partner ADC development programmes including PermaLink® and PermaLink® + toxin payloads.
We are constantly reviewing the ADC landscape and are always keen to talk with research groups that are developing ADC-relevant assets. Iksuda is flexible in its approach to collaborative development with its partners to accelerate ADC research and development.
If you are interested in talking with us about licensing or research collaboration, please contact us.